Further modification on phenyl acetic acid based quinolines as liver X receptor modulators

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 10, 2007, Pages 3321-3333

  Hu, Baihua ^a   Jetter, James ^a   Kaufman, David ^a   Singhaus, Robert ^a   Bernotas, Ronald ^a   Unwalla, Rayomand ^a   Quinet, Elaine ^a   Savio, Dawn ^a   Halpern, Anita ^a   Basso, Michael ^a   Keith, James ^a   Clerin, Valerie ^a   Chen, Liang ^a   Liu, Qiang Yuan ^a   Feingold, Irene ^a   Huselton, Christine ^a   Azam, Farooq ^a   Goos Nilsson, Annika ^b   Wilhelmsson, Anna ^b   Nambi, Ponnal ^a   Wrobel, Jay ^a   more..

^a PFIZER INC   (United States)

^b Karo Bio   (Sweden)

Author keywords

Liver X receptor (LXR); LXR agonists; Phenyl acetic acid; Quinoline

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; 3 CHLORO 4 [[3 [(3 PHENYL 7 PROPYL 6 BENZOFURANYL)OXY]PROPYL]THIO]PHENYLACETIC ACID; [4 [[[3 (3 BENZYL 8 CHLOROQUINOLIN 4 YL)PHENYL]AMINO]METHYL]PHENYL]ACETIC ACID; [4 [[[3 (3 BENZYL 8 METHYLQUINOLIN 4 YL)PHENYL]AMINO]METHYL]PHENYL]ACETIC ACID; ABC TRANSPORTER A1; L 796449; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENYLACETIC ACID DERIVATIVE; PIRINIXIC ACID; QUINOLINE DERIVATIVE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CARBOXYLIC ACIDS; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; DNA-BINDING PROTEINS; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENYLACETATES; QUINOLINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT PROTEINS; SOLVENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS);

MUS;

EID: 34047132823     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.03.013     Document Type: Article

References (18)

1. Bulliyya G. Asia Pacific J. Clin. Nutr. 9 (2000) 289-297
2. For recent reviews, see:. Bradley M.N., and Tontonoz P. Drug Discovery Today: Ther. Strateg. (2005) 97-103
3. Collins J.L. Curr. Opin. Drug Discovery Dev. 7 (2004) 692-702
4. Jaye M. Curr. Opin. Invest. Drugs 4 (2003) 1053-1058
5. Lund E.G., Menke J.G., and Sparrow C.P. Arterioscler. Thromb. Vasc. 237 (2003) 1169-1177
6. For a review on recently reported LXR agonists in patents, see:. Bennett D.J., Brown L.D., Cooke A.J., and Edwards A.S. Expert Opin. Ther. Pat. 16 (2006) 1673-1699
7. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Blanchard D.E., Spencer T.A., and Willson T.M. J. Biol. Chem. 272 (1997) 3137-3140
8. Spencer T.A., Gayen A.K., Phirwa S., Nelson J.A., Taylor F.R., Kandutsch A.A., and Erickson S.K. J. Biol. Chem. 260 (1985) 13391-13394
9. Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M.C., Moore L.B., Parks D.J., Wilson J.G., Tippin T.K., Binz J.G., Plunket K.D., Morgan D.G., Beaudet E.J., Whitney K.D., Kliewer S.A., and Willson T.M. J. Med. Chem. 45 (2002) 1963-1966
10. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., and Shan B. Gene Dev. 14 (2000) 2831-2838
11. Hu B., Collini M., Unwalla R., Miller C., Singhaus R., Quinet E., Savio D., Halpern A., Basso M., Keith J., Clerin V., Chen L., Resmini C., Liu Q.-Y., Feingold I., Huselton C., Azam F., Farnegardh M., Enroth C., Bonn T., Goos-Nilsson A., Wilhelmsson A., Nambi P., and Wrobel J. J. Med. Chem. 49 (2006) 6151-6154
12. For the details of ABCA1 and SREBP-1c assays, see:. Quinet E.M., Savio D.A., Halpern A.R., Chen L., Miller C.P., and Nambi P. J. Lipid Res. 45 (2004) 1929-1942
13. For WY-14643, see:. Santilli A.A., Scotese A.C., and Tomarelli R.M. Experientia 30 (1974) 1110-1111
14. For Rosiglitazone, see:. Oakes N.D., Kennedy C.J., Jenkins A.B., Laybutt D.R., Chisholm D.J., and Kraegen E.W. Diabetes 43 (1994) 1203-1210
15. For L-796449, see:. Lawrence J.W., Li Y., Chen S., DeLuca J.G., Berger J.P., Umbenhauer D.R., Moller D.E., and Zhou G. J. Bio. Chem. 276 (2001) 31521-31527
16. Biagi G., Livi O., Scartoni V., and Verugi E. Farmaco, Edizione Scientifica 43 (1988) 597-611
17. Veverka, M.; Bohac, A.; Kriz, M.; Varga, I. WO 2004043922; Chem. Abstr. 2004, 141, 7026.
18. Ackerley N., Brewster A.G., Brown G.R., Clarke D.S., Foubister A.J., Griffin S.J., Hudson J.A., Smithers M.J., and Whittamore P.R.O. J. Med. Chem. 38 (1995) 1608